The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I don't think any of us will see £5 a share, when the buyout is announced shares will be suspended and will probably open for trading around 20 quid.
A lot of you traders will be locked out.
Call me a ramper if you like, I don't care.
Avacta (LON: AVCT)
Avacta is currently proceeding with clinical trials of its flagship AVA6000 — which it hopes will deliver ‘chemotherapy without the side effects.’
The company recently announced that the first patient of the fifth cohort of the flagship AVA6000 Phase 1a Dose Escalation Study has been dosed with the treatment in the UK — this first in-human phase I trial includes MHRA approval for higher dosages — at a level of 250mg/m2. The idea is to find out the maximum tolerable dose for further clinical trials.
CEO Alastair Smith notes that ‘the recent confirmation of release of active chemotherapy in the tumour tissue and the safety data being generated in the ALS-6000-101 study are providing detailed insights.’
The company has also opened two US Clinical Investigator Sites for AVA6000 Phase 1, one at the Memorial Sloan Kettering Cancer Center and the second at the Fred Hutch Cancer Center. Enrolment for soft tissue sarcoma patients has begun, with trials led by globally renowned oncologists Dr William Tap and Dr Lee Cramer.
Avacta has hinted that phase 1B may be conducted initially across the pond, claiming that stateside is ‘uniquely positioned’ for further research. CDO Neil Bell has highlighted the recent ‘major milestone,’ and plans to ‘build the clinical evidence base for the safety and tolerability of AVA6000.’
Further clinical success could see the share price rocket — and a buyout or US listing — could come at any time.
We need all the helpful press coverage we can get.